JP2013523686A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523686A5
JP2013523686A5 JP2013501816A JP2013501816A JP2013523686A5 JP 2013523686 A5 JP2013523686 A5 JP 2013523686A5 JP 2013501816 A JP2013501816 A JP 2013501816A JP 2013501816 A JP2013501816 A JP 2013501816A JP 2013523686 A5 JP2013523686 A5 JP 2013523686A5
Authority
JP
Japan
Prior art keywords
vaccine according
polypeptide
vaccine
antigen
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013501816A
Other languages
English (en)
Japanese (ja)
Other versions
JP5942296B2 (ja
JP2013523686A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/054866 external-priority patent/WO2011120994A1/en
Publication of JP2013523686A publication Critical patent/JP2013523686A/ja
Publication of JP2013523686A5 publication Critical patent/JP2013523686A5/ja
Application granted granted Critical
Publication of JP5942296B2 publication Critical patent/JP5942296B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013501816A 2010-03-29 2011-03-29 少なくとも1つのcxxcモチーフを含むポリペプチドと異種抗原とを含む医薬組成物、及びその使用 Expired - Fee Related JP5942296B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10305317 2010-03-29
EP10305317.9 2010-03-29
PCT/EP2011/054866 WO2011120994A1 (en) 2010-03-29 2011-03-29 Pharmaceutical compositions comprising a polypeptide comprising at least one cxxc motif and heterologous antigens and uses thereof

Publications (3)

Publication Number Publication Date
JP2013523686A JP2013523686A (ja) 2013-06-17
JP2013523686A5 true JP2013523686A5 (enExample) 2014-05-15
JP5942296B2 JP5942296B2 (ja) 2016-06-29

Family

ID=42312972

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013501816A Expired - Fee Related JP5942296B2 (ja) 2010-03-29 2011-03-29 少なくとも1つのcxxcモチーフを含むポリペプチドと異種抗原とを含む医薬組成物、及びその使用

Country Status (12)

Country Link
US (1) US9801927B2 (enExample)
EP (2) EP3156068B1 (enExample)
JP (1) JP5942296B2 (enExample)
KR (1) KR101866301B1 (enExample)
CN (1) CN103002909B (enExample)
AR (1) AR081809A1 (enExample)
BR (1) BR112012024872B1 (enExample)
CA (1) CA2792174C (enExample)
ES (1) ES2619077T3 (enExample)
SG (1) SG183977A1 (enExample)
UY (1) UY33297A (enExample)
WO (1) WO2011120994A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2657480T3 (es) 2006-08-11 2018-03-05 Life Sciences Research Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
EP2719396B1 (en) 2008-02-14 2017-06-21 Life Sciences Research Partners VZW Immunotherapy targeting intracellular pathogens
EP2623115A1 (en) 2008-02-14 2013-08-07 Life Sciences Research Partners VZW Immunogenic control of tumours and tumour cells
ES2584430T3 (es) * 2008-02-14 2016-09-27 Life Sciences Research Partners Vzw Estrategias para prevenir y/o tratar las respuestas inmunitarias a los alofactores solubles
EP2623124A1 (en) 2008-02-14 2013-08-07 Life Sciences Research Partners VZW Elimination of immune responses to viral vectors
US9248171B2 (en) * 2008-02-14 2016-02-02 Imcyse Sa Immunogenic peptides and their use in transplantation
JP6173915B2 (ja) 2010-11-25 2017-08-02 イムナテ・ソシエテ・ア・レスポンサビリテ・リミテImnate Sarl 感染症、自己免疫疾患、同種因子に対する免疫応答、アレルギー性疾患、腫瘍、移植片拒絶反応、および、遺伝子療法または遺伝子ワクチン接種のために使用されるウイルスベクターに対する免疫応答の予防および/または治療における使用のための免疫原性ペプチド
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
JP2014212722A (ja) * 2013-04-24 2014-11-17 学校法人加計学園 八面体構造を有するb型肝炎ウイルス様粒子結晶
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
US10729791B2 (en) * 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
EP3352782B1 (en) 2015-09-25 2021-03-31 ImCyse SA Improved methods and compounds for eliminating immune responses to therapeutic agents
KR20180134935A (ko) 2016-04-19 2018-12-19 임시스 에스에이 신규 면역원성 CD1d 결합 펩티드
JP7102430B2 (ja) 2017-03-09 2022-07-19 アンシス・エスア 糖尿病の治療のためのペプチド及び方法
EP4144752A1 (en) * 2021-09-02 2023-03-08 Sorbonne Universite Viral-like particles for the treatment or prevention of an infection by a coronaviridae virus

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165469A (en) * 1988-01-13 2000-12-26 University Of Virginia Recombinant Entamoeba histolytica lectin subunit peptides and reagents specific for members of the 170 kD subunit multigene family
EP2172214A3 (en) * 1999-03-12 2011-03-16 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
EP1201750A1 (en) * 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
KR101228376B1 (ko) 2002-07-18 2013-01-31 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
US7943396B2 (en) * 2004-06-22 2011-05-17 The Regents Of The University Of California Peptide-coated nanoparticles with graded shell compositions
DE502004010408D1 (de) 2004-07-02 2009-12-31 Schoelly Fiberoptic Gmbh Vorrichtung und verwendung der vorrichtung zur aufnahme und verarbeitung eines bildes
WO2006026746A2 (en) 2004-08-31 2006-03-09 The Government Of United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to separate and expand antigen-specific t cells
GB0426641D0 (en) * 2004-12-03 2005-01-05 Bioactive Protein Delivery The Protein delivery system
ATE517613T1 (de) 2006-04-13 2011-08-15 Midatech Ltd Nanoteilchen mit drei verschiedenen liganden zur auslösung einer immunantwort gegen infektiöse mittel
AU2007345768B2 (en) * 2006-07-27 2013-08-01 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
ES2657480T3 (es) * 2006-08-11 2018-03-05 Life Sciences Research Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
EP2199301A1 (en) 2008-12-19 2010-06-23 DKFZ Deutsches Krebsforschungszentrum Immunogenic polypeptides comprising a scaffold polypeptide and a L2 polypeptide or fragment thereof

Similar Documents

Publication Publication Date Title
JP2013523686A5 (enExample)
Gupta et al. Platforms, advances, and technical challenges in virus-like particles-based vaccines
Huang et al. Escherichia coli-derived virus-like particles in vaccine development
US12472244B2 (en) Immunogenic compositions and uses thereof
Rockman et al. New technologies for influenza vaccines
Jackman et al. Rupture of lipid vesicles by a broad-spectrum antiviral peptide: influence of vesicle size
SG131116A1 (en) Functional influenza virus-like particles (vlps)
EP2361930A3 (en) Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
JP2016519933A5 (enExample)
EP4609876A3 (en) Anti-human papillomavirus 16 e7 t cell receptors
JP2012010713A5 (enExample)
JP2010011868A5 (enExample)
JP2019513005A5 (enExample)
JP2020506690A5 (enExample)
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
CN106008716A (zh) 呼吸道合胞病毒抗原组合物和方法
JP2019536426A5 (enExample)
WO2009055491A3 (en) Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres
JP2016539641A5 (enExample)
Aggarwal et al. Immune therapy targeting E6/E7 oncogenes of human papillomavirus type 6 (HPV-6) reduces or eliminates the need for surgical intervention in the treatment of HPV-6 associated recurrent respiratory papillomatosis
JP2010538619A5 (enExample)
JP2010532656A5 (enExample)
Alhashimi et al. Nonhuman adenoviral vector-based platforms and their utility in designing next generation of vaccines for infectious diseases
JP2009501901A5 (enExample)
Zhuang et al. Harnessing T-cells for enhanced vaccine development against viral infections